Biofrontera Stock (NASDAQ:BFRI)
Previous Close
$0.84
52W Range
$0.65 - $2.22
50D Avg
$0.96
200D Avg
$1.02
Market Cap
$7.11M
Avg Vol (3M)
$121.44K
Beta
0.37
Div Yield
-
BFRI Company Profile
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
BFRI Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Government and Payor Rebates | $310.00K | $264.00K | $157.00K |
| Co-pay Assistance Program | $165.00K | $675.00K | - |
| Returns | $52.00K | $53.00K | $180.00K |
| Prompt Pay Discounts | $6.00K | $67.00K | $7.00K |
| CoPay Assistance Program | - | - | $374.00K |
Fiscal year ends in Dec 24 | Currency in USD
Peer Comparison
| Ticker | Company |
|---|---|
| AKAN | Akanda Corp. |
| PROC | Procaps Group S.A. |
| SHPH | Shuttle Pharmaceuticals Holdings, Inc. |
| CPIX | Cumberland Pharmaceuticals Inc. |
| EVOK | Evoke Pharma, Inc. |
| SXTC | China SXT Pharmaceuticals, Inc. |
| IXHL | Incannex Healthcare Limited |
| RGC | Regencell Bioscience Holdings Limited |
| PTPI | Petros Pharmaceuticals, Inc. |
| PRFX | PainReform Ltd. |